In the Clinic: Contraception

Annals of Internal Medicine

Volumn 157, Issue 7, 2012, Pages

  Woodhams, Elisabeth J ^a   Gilliam, Melissa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; ETHINYLESTRADIOL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; ULIPRISTAL;

COITUS; CONDOM; CONSULTATION; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DYSMENORRHEA; ENDOMETRIUM CANCER; HEALTH CARE COST; HUMAN; HYSTEROSCOPY; INSTRUMENT STERILIZATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LONG ACTING REVERSIBLE CONTRACEPTION; MEDICAL EDUCATION; MIGRAINE; NOTE; ORAL CONTRACEPTION; PHYSICIAN; PREGNANCY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; SALPINGECTOMY; SEXUALLY TRANSMITTED DISEASE; THERAPY EFFECT; VASECTOMY; VENOUS THROMBOEMBOLISM;

CONDOMS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE DEVICES, FEMALE; CONTRACEPTIVES, POSTCOITAL; COSTS AND COST ANALYSIS; COUNSELING; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; PATIENT EDUCATION AS TOPIC; PREGNANCY; PREGNANCY, UNPLANNED; QUALITY OF HEALTH CARE; RISK ASSESSMENT; STERILIZATION, REPRODUCTIVE; UNITED STATES;

EID: 84868322293     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: None     Document Type: Note

References (55)

1. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84:478-85. [PMID: 22018121]
2. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of longacting reversible contraception. N Engl J Med. 2012;366:1998-2007. [PMID: 22621627]
3. Trussell J. Contraceptive efficacy. In: Hatcher RA, Nelson AL, et al, eds. Contraceptive Technology. New York, NY: Ardent Media; 2008
4. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev. 2010: CD007541. [PMID: 20091638]
5. Cates W. Vaginal barriers and spermicides. In: Hatcher RA, Nelson AL, et al, eds. Contraceptive Technology. New York, NY: Ardent Media; 2008.
6. Jamieson DJ, Costello C, Trussell J, et al; US Collaborative Review of Sterilization Working Group. The risk of pregnancy after vasectomy. Obstet Gynecol. 2004;103:848-50. [PMID: 15121555]
7. Peterson HB, Xia Z, Hughes JM, Wilcox LS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol. 1996;174:1161-8; discussion 1168-70. [PMID: 8623843]
8. Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol. 2007;50:907-17. [PMID: 17982333]
9. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13 Suppl 1: 4-12. [PMID:18330813]
10. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77: 10-21. [PMID:18082661]
11. Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception. 2006;74:451-7. [PMID: 17157101]
12. Creinin MD, Meyn LA, Borgatta L, et al. Multicenter comparison of the contraceptive ring and patch: a randomized controlled trial. Obstet Gynecol. 2008;111:267-77. [PMID: 18238962]
13. Lopez LM, Grimes DA, Gallo MF, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2010: CD003552. [PMID: 20238323]
14. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77:S13-8. [PMID: 11849631]
15. Warner L. Male condoms. In: Hatcher RA, Nelson AL, et al, eds. Contraceptive Technology. New York, NY: Ardent Media; 2008: 297-316.
16. Rosenberg MJ, Waugh MS. Latex condom breakage and slippage in a controlled clinical trial. Contraception. 1997;56:17-21. [PMID: 9306027]
17. Trussell J, Sturgen K, Strickler J, 1994;26:66-72. [PMID: 8033980]
18. Stewart F, Van Look J. Emergency contraception. In: Hatcher RA, Nelson AL, et al, eds. Contraceptive Technology. New York, NY: Ardent Media; 2008.
19. Jayakrishnan K, Baheti SN. Laparoscopic tubal sterilization reversal and fertility outcomes. J Hum Reprod Sci. 2011;4:125-9. [PMID:22346079]
20. Harada T, Momoeda M, Terakawa N, Taketani Y, Hoshiai H. Evaluation of a lowdose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2011;95:1928-31. [PMID: 21420678]
21. Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod. 2006;21:2304-11. [PMID: 16763008]
22. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol. 2001;98: 771-8. [PMID:11704167]
23. Stewart FH, Kaunitz AM, Laguardia KD,. Extended use of transdermal norelgestromin/ ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005;105: 1389-96. [PMID:15932834]
24. Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care. 2002;7 Suppl 3:27-34. [PMID: 12659404].
25. Lopez LM, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012;2:CD006586.
26. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2012;6: CD004425. [PMID:22696343]
27. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010;17: R263-71. [PMID:20870686]
28. Crane K. Oral contraceptives as ovarian cancer prevention. J Natl Cancer Inst. 2011;103:1286-8. [PMID: 21852259]
29. Cibula D, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010; 16: 631-50. [PMID:20543200]
30. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006: CD003855. [PMID: 16625593]
31. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a singlerod implantable contraceptive containing etonogestrel. Contraception. 2005;71:319-26. [PMID: 15854630]
32. Lockhat FB, Emembolu JO, Konje JC. The efficacy, sideeffects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intrauterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789-93. [PMID: 15608040]
33. Lethaby AE, Cooke I, Rees M. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2005: CD002126. [PMID: 16235297]
34. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrelreleasing intrauterine system: long-term follow-up. Maturitas. 2007;57:210-3. [PMID: 17270370]
35. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-8. [PMID: 7500749]
36. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010;81:16-21. [PMID: 20004268]
37. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1996;348: 498-505. [PMID:8757151]
38. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996;347:1713-27. [PMID: 8656904]
39. Marchbanks PA, Curtis KM, Mandel MG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012;85:342-50. [PMID: 22067757]
40. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-32. [PMID: 12087137]
41. Gallo MF, Grimes DA, Lopez LM, Schulz KF, d'Arcangues C. Combination injectable contraceptives for contraception. Cochrane Database Syst Rev. 2008: CD004568. [PMID:18843662]
42. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Nonsteroidal antiinflammatory drugs for heavy bleeding or pain associated with intrauterinedevice use. Cochrane Database Syst Rev. 2006: CD006034. [PMID: 17054271]
43. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database Syst Rev. 2001: CD001327. [PMID: 11405986]
44. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 121: Longacting reversible contraception: Implants and intrauterine devices. Obstet Gynecol. 2011;118: 184-96. [PMID:21691183]
45. The U.S. Medical Eligibility Criteria for Contraceptive Use. MMWR Morb Mortal Wkly Rep. 2010;59 (RR04):1-85.
46. Trussell J. Choosing a contraceptive: efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, et al, eds. Contraceptive Technology. New York, NY: Ardent Media; 2009.
47. Barnhart KT, Schreiber CA. Return to fertility following discontinuation of oral contraceptives. Fertil Steril. 2009;91: 659-63. [PMID:19268187]
48. Hofmeyr GJ, Singata M, Lawrie TA. Copper containing intrauterine devices versus depot progestogens for contraception. Cochrane Database Syst Rev. 2010: CD007043. [PMID:20556773]
49. Speroff L, Darney PD. The postpartum Period, Breastfeeding, and Contraception. A Clinical Guide for Contraception. Philadelphia, PA: Lippincott Williams & Wilkins; 2011
50. Grimes D, Schulz K, Van Vliet H, Stanwood N. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev. 2003: CD003036. [PMID: 12535449]
51. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception. 2009; 79: 5-14. [PMID:19041435]
52. Insurance Coverage of Contraceptives. Guttmacher State Policies in Brief. 2012. www.guttmacher.org/statecenter/ spibs/spib_ICC.pdf. Accessed 9 August 2012.
53. Eisenberg DL, Stika C, Desai A, Baker D, Yost KJ. Providing contraception for women taking potentially teratogenic medications: a survey of internal medicine physicians' knowledge, attitudes and barriers. J Gen Intern Med. 2010;25:291-7. [PMID: 20087677]
54. Lohr PA, Schwarz EB, Gladstein JE, et al. Provision of contraceptive counseling by internal medicine residents. J Womens Health (Larchmt). 2009;18:127-31. [PMID:19072725]
55. Lohr PA, Schwarz EB, Gladstein JE, et al. Provision of contraceptive counseling by internal medicine residents. International Family Planning Perspectives. 2001;27:63-70.